CompletedPhase 1/2

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

United States138 participantsStarted 2008-03

Plain-language summary

Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors

Who can participate

Age range10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ewing's family of tumors * Current disease state for which there is no curative therapy Exclusion Criteria: * Prior anti-IGF-1R therapy * Concurrent treatment with other anti-cancer agents

What they're measuring

Objective Response Rate (ORR)

Timeframe: Baseline and every cycle (4 weeks), for up to 6 cycles

Trial details

NCT IDNCT00560235

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-03

Results submitted2013-10-24

View on ClinicalTrials.gov More Ewing's Sarcoma Family of Tumors trials